TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Enterprise value to EBITDA ratio
Latest
-0.54
↑ 88% vs avg
Percentile
P67
Within normal range
Streak
2 yr
Consecutive growthExpanding
Average
-4.54
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| 2025 | -0.54 | +75.1% |
| 2024 | -2.16 | +49.2% |
| 2023 | -4.26 | -7803.8% |
| 2022 | -0.05 | -105.1% |
| 2021 | 1.05 | +111.2% |
| 2020 | -9.38 | +42.9% |
| 2019 | -16.43 | - |